Figure 7 shows the effects of DPP-4 inhibitors and placebo in these studies. The DPP-4 inhibitors reduced HbA1c by 0.5–0.8% (5–8 mmol/mol) after 24–26 weeks. Body weight did not change significantly and all DPP-4 inhibitors were well-tolerated. There was no difference in the (low) numbers of confirmed hypoglycemia between DPP-4 inhibition and placebo and the occurrence of adverse events did not differ between the study groups except a slight increase in gastrointestinal adverse events in one of the studies (66). Here, DPP4 is linked to Hypoglycemia.